Ben­ny Sorensen

Don’t let the short week de­ceive you. Peer Re­view has a lot to get to:

→ When our Nicole De­Feud­is pro­filed new Co­di­ak CMO Jen­nifer Whel­er, she al­so wrote that Ben­ny Sorensen would be tak­ing on the role of SVP of strate­gic projects af­ter head­ing up clin­i­cal de­vel­op­ment. That didn’t last long.

We’ve learned that Sorensen has re­signed to lead Dan­ish biotech Hemab Ther­a­peu­tics as CEO. Backed by No­vo Hold­ings, Hemab is a three-year-old com­pa­ny that de­vel­ops bis­pe­cif­ic an­ti­bod­ies for rare bleed­ing dis­or­ders that had been helmed by co-founder Jo­han Faber. Sorensen, an Al­ny­lam vet, will still be con­nect­ed to Co­di­ak as a mem­ber of the sci­en­tif­ic ad­vi­so­ry board and a clin­i­cal con­sul­tant.

→ We’re stay­ing in Den­mark as Michael Pehl has been named CEO at Ad­cen­do, fo­cused on AD­Cs and equipped with the largest Se­ries A round for a biotech in the land of Bor­gen. As CEO of Ger­man CAR-T play­er GEMoaB, Pehl helped join forces with Black­stone and CRISPR big­wig In­tel­lia to launch a new CAR-T biotech in late June. Black­stone plunked down $250 mil­lion on the in­vest­ment. Pehl, the ex-pres­i­dent and CEO of Im­munomedics, was pres­i­dent of on­col­o­gy (among oth­er po­si­tions) dur­ing his tenure with Cel­gene from 2006-17.

Ax­el Hoos

Glax­o­SmithK­line is los­ing its on­col­o­gy head as Ax­el Hoos hits the ex­it to man the ship at stealthy biotech Scor­pi­on Ther­a­peu­tics as CEO. Dur­ing his nine-year gig with the UK phar­ma gi­ant, Hoos over­saw a long-await­ed turn­around at GSK on­col­o­gy af­ter the com­pa­ny opt­ed to of­fload its en­tire late on­col­o­gy pipeline to Swiss drug­mak­er No­var­tis in March 2015. Most re­cent­ly, Hoos served as GSK’s SVP, R&D gov­er­nance chair and ther­a­peu­tic area head on­col­o­gy.

Christo­pher Gior­dano

→ We have a suc­ces­sion plan in place at Tenax Ther­a­peu­tics in the Re­search Tri­an­gle, as Christo­pher Gior­dano grabs the top spot and An­tho­ny Di­Ton­no re­tires as CEO. Gior­dano of­fi­cial­ly takes over at Tenax on Ju­ly 14 af­ter more than a dozen years with IQVIA, three of those as pres­i­dent of IQVIA Biotech. Di­Ton­no had led the com­pa­ny since June 1, 2018 and had been on the board of di­rec­tors since 2011. Tenax has hit its share of tur­bu­lence in the past — af­ter lead can­di­date lev­osi­men­dan tum­bled bad­ly in Phase III in ear­ly 2017, giv­ing its stock a thrash­ing, then-CEO John Kel­ley re­signed a cou­ple months lat­er. Con­cur­rent with the Gior­dano news, Tenax is un­load­ing $10 mil­lion in stocks to an in­vestor not iden­ti­fied in the re­lease.

→ Hop­ing to get back in the good graces of in­vestors in the Duchenne sweep­stakes, Ilan Gan­ot has lined up three new ex­ecs at Sol­id Bio­sciences a month af­ter adding chief reg­u­la­to­ry of­fi­cer Iman Bar­ilero to the staff. Up first, Rox­ana Don­isa Dreghi­ci leaves Roche to take on the role of SVP, clin­i­cal de­vel­op­ment for Sol­id Bio. Don­isa Greghi­ci was the Swiss phar­ma’s glob­al de­vel­op­ment lead/as­so­ciate group med­ical di­rec­tor, neu­ro­science.

Al­so at Sol­id Bio, Amer­i­can Ex­press vet Caitlin Lowie (VP, com­mu­ni­ca­tions & IR) hits the scene af­ter her time at Stal­largenes Greer as se­nior di­rec­tor, com­mu­ni­ca­tions and strate­gic growth ini­tia­tives. And Al­i­son Kessler (VP, le­gal cor­po­rate & IP), for­mer­ly glob­al head of patents for No­var­tis’ over-the-counter busi­ness, was briefly chief le­gal of­fi­cer with Cosette Phar­ma­ceu­ti­cals.

Lou Ar­cu­di

Lou Ar­cu­di took over for Mil­len­do co-founder Ju­lia Owens as CEO af­ter a Phase I im­plo­sion of NK3R an­tag­o­nist MLE-301 left an emp­ty cup­board and the op­tion of a sale on the ta­ble. A merg­er with Tem­pest Ther­a­peu­tics has since closed, and Ar­cu­di is mov­ing on to Amolyt Phar­ma — a mak­er of pep­tides for en­docrine and meta­bol­ic dis­eases — as CFO. Ar­cu­di, a Gen­zyme fi­nance alum, was CFO and SVP of op­er­a­tions dur­ing his 11 years at Idera Phar­ma­ceu­ti­cals. Pri­or to Idera, he served as Pep­ti­m­mune’s VP of fi­nance and ad­min­is­tra­tion.

That’s not all: Amolyt has added Janssen alum and Ix­altis chief de­vel­op­ment of­fi­cer Elis­a­beth Svan­berg to the board of di­rec­tors along with long­time Am­gen ex­ec James Hind­man.

→ CRISPR up­start Lo­can­abio, helmed by Jim Burns and awash with cash from a $100 mil­lion Se­ries B, has re­cruit­ed John Leonard as CSO and Ed­ward Con­ner as CMO. Leonard (not to be con­fused with the In­tel­lia CEO) makes the switch from CRISPR Ther­a­peu­tics, where he led hema­tol­ogy and in vi­vo re­search and trans­la­tion, and he al­so was head of meta­bol­ic and neu­ro­mus­cu­lar re­search in Sanofi Gen­zyme’s rare dis­ease unit. Mean­while, Con­ner ex­its Au­dentes (now Astel­las Gene Ther­a­pies) af­ter his tenure as CMO and has held that same ti­tle be­fore with Sang­amo. He was pre­vi­ous­ly VP of glob­al clin­i­cal de­vel­op­ment at Ul­tragenyx be­fore his run of C-suite ap­point­ments.

Sarah Lu

BioShin, the Bio­haven sub­sidiary in Shang­hai that hit pay dirt back in Sep­tem­ber with a $60 mil­lion round led by Or­biMed, has bol­stered its lead­er­ship with CMO Sarah Lu and chief com­mer­cial of­fi­cer Mary Ma. Lu is a 13-year UCB vet and for­mer clin­i­cal de­vel­op­ment ex­ec at Sim­cere who was re­cent­ly SVP, pres­i­dent of glob­al de­vel­op­ment for Shang­hai Green Val­ley. Ma tack­les the CCO role af­ter a string of Big Phar­ma stops in Chi­na in­clud­ing Eli Lil­ly, Ab­b­Vie and — just be­fore this move to BioShin — Mer­ck, where she was a VP and led the hos­pi­tal spe­cial­ty care busi­ness unit.

Caren Dear­dorf

→ Sev­er­al weeks af­ter los­ing CMO and head of R&D John Davis for “fam­i­ly rea­sons,” Ma­gen­ta Ther­a­peu­tics is re­load­ing in an­oth­er po­si­tion as Caren Dear­dorf takes the chief com­mer­cial of­fi­cer job. Dear­dorf, who was pre­vi­ous­ly CCO at Ohana Bio­sciences, closed out her eight years at Bio­gen in 2019 as VP, glob­al prod­uct de­vel­op­ment & com­mer­cial­iza­tion lead for Spin­raza and the SMA port­fo­lio.

In a re­lat­ed de­vel­op­ment, ex-Ma­gen­ta chief op­er­at­ing and fi­nan­cial of­fi­cer Ja­son Ryan is now on the board of di­rec­tors at Se­ma4, which merged with the Cas­din Cap­i­tal SPAC named CM Life Sci­ences in Feb­ru­ary.

→ Part­ner­ing with Co­herus on the an­ti-PD-1 tori­pal­imab, Jun­shi Bio­sciences has se­lect­ed Wei Qian as chief com­mer­cial of­fi­cer. Qian spent the last five years as a VP at Roche Chi­na and the pre­vi­ous 10 play­ing a bevy of po­si­tions at As­traZeneca in Chi­na, in­clud­ing VP of the GAA busi­ness unit (gas­troin­testi­nal sys­tem, anes­the­sia and an­ti-in­fec­tion). Jun­shi and Co­herus un­veiled da­ta at last month’s AS­CO for na­sopha­ryn­geal can­cer that nudges tori­pal­imab in­to the con­ver­sa­tion in a crowd­ed PD-1/L-1 space.

Nikhil Goel

Sean Mc­Clain’s Ab­sci filed for an IPO last week, shoot­ing for the $100 mil­lion fig­ure that’s be­come a pop­u­lar place­hold­er. A slight styl­is­tic change to the com­pa­ny name isn’t the on­ly oth­er move Ab­sci has made, with Nikhil Goel step­ping in as CBO and Sarah Ko­r­man as gen­er­al coun­sel. Goel jumps over to the pro­tein print­ing biotech based in Wash­ing­ton state af­ter five years at Cred­it Su­isse and was a di­rec­tor in the M&A busi­ness. Af­ter a stint as head of in­tel­lec­tu­al prop­er­ty for fi­nal drug prod­ucts at Am­gen, Ko­r­man then be­came Neu­vo­gen’s gen­er­al coun­sel and cor­po­rate sec­re­tary in 2019.

Out­look Ther­a­peu­tics has nabbed Rus­sell Tre­nary as the com­pa­ny’s pres­i­dent and CEO, suc­ceed­ing Lawrence Keny­on who will con­tin­ue to serve as CFO. Tre­nary joins the com­pa­ny from In­n­Fo­cus, where he served as pres­i­dent and CEO in a sev­en-year stint be­fore its ac­qui­si­tion by San­ten Phar­ma­ceu­ti­cal. Be­fore that, Tre­nary was pres­i­dent and CEO of glob­al med­ical de­vice com­pa­ny G&H Or­tho­don­tics and served in a va­ri­ety of roles at Sun­rise Tech­nolo­gies, Vi­daMed and Al­ler­gan.

Sabine Dauge­lat

→ With the ra­dio­phar­ma­ceu­ti­cals field siz­zling, Ger­many-based ITM is bring­ing in Sabine Dauge­lat as COO af­ter nab­bing $109 mil­lion in loan fi­nanc­ing back in April. Dauge­lat, once the se­nior glob­al pro­gram team di­rec­tor at San­doz, ends her two-year as­so­ci­a­tion with Pieris Phar­ma­ceu­ti­cals as ex­ec­u­tive di­rec­tor, head of project lead­er­ship. Rayze­Bio and Ak­tis are among the oth­er play­ers who have joined the ra­dio­phar­ma band­wag­on just in the past year.

Rob Brain­in

→ As Marc Sta­p­ley takes up the CEO man­tle from Bon­nie An­der­son, Ve­r­a­cyte has locked in two oth­er ex­ecs with EVP and CBO Rob Brain­in and SVP and chief in­for­ma­tion of­fi­cer Bill Zondler. Brain­in, the erst­while CEO of Ge­nu­ity Sci­ence, was once VP and gen­er­al man­ag­er of Il­lu­mi­na’s life sci­ences and ap­plied ge­nomics busi­ness. Fleet­ing­ly the con­sult­ing CIO at Ax­o­vant, Zondler comes to Ve­r­a­cyte from an­oth­er CIO post at Bio­ther­a­nos­tics.

David He­witt has signed on as CMO of Bay Area non-opi­oid pain man­age­ment biotech Al­lay Ther­a­peu­tics, which made its de­but in May with ster­ling Phase I pain re­lief da­ta that showed they “were on to some­thing that pre­cip­i­tat­ed the com­ing-out par­ty,” as CEO Adam Gri­d­ley told End­points News. He­witt, the ex-Sy­neos Health CMO who broke in­to bio­phar­ma at J&J and then mi­grat­ed to the neu­rol­o­gy group at Mer­ck, is the for­mer SVP of clin­i­cal de­vel­op­ment for both Nu­ra Bio and Karuna Ther­a­peu­tics.

Adam Cut­ler

Q32 Bio — the Cam­bridge, MA biotech where CMO Ja­son Cam­pagna land­ed af­ter his time at In­ter­cept — has locked in Adam Cut­ler as CFO. Cut­ler makes the switch af­ter al­most four years in the same post at Austin-based Mol­e­c­u­lar Tem­plates, which struck an I/O deal in Feb­ru­ary with Bris­tol My­ers Squibb worth $70 mil­lion up­front. Be­fore jump­ing to that CFO spot, he was SVP of cor­po­rate af­fairs at Ar­bu­tus. Mak­ing the most progress thus far at Q32 Bio is an an­ti-IL-7Ra an­ti­body in Phase I dubbed ADX-914.

Bio­phytis isn’t one of the flashier com­pa­nies to go pub­lic in 2021; nev­er­the­less, the French biotech did price its IPO at $16.75 mil­lion af­ter with­draw­ing its first try, and its lead drug for sar­cope­nia is al­so in Phase II/III for Covid-19 pa­tients with pneu­mo­nia. This week Bio­phytis has fleshed out its C-suite with Jean Mar­i­ani as CMO and Benoit Canolle as CBO. Mar­i­ani, the di­rec­tor of L’In­sti­tut de la Longévité, is al­so pro­fes­sor emer­i­tus at Sor­bonne Uni­ver­si­ty. When his 11-year run at Sanofi drew to a close in 2015, Canolle was project man­ag­er for the im­muno-in­flam­ma­tion de­vel­op­ment fran­chise. For the last year, he’s been Pierre Fab­re’s head of cor­po­rate med­ical port­fo­lio & project di­rec­tion.

Just one more thing, as Colum­bo liked to say: Claude Al­lary is in line to re­place Jean Franchi on Bio­phytis’ board of di­rec­tors.

Tina Bea­mon

→ San Diego can­cer biotech MEI Phar­macol­lab­o­rat­ing with Ky­owa Kirin on PI3Kδ in­hibitor zan­delis­ibhas ap­point­ed Tina Bea­mon chief com­pli­ance of­fi­cer. Bea­mon, who just filled the same role at Karyopharm, has al­so been Alex­ion’s ex­ec­u­tive di­rec­tor of com­pli­ance and ethics. Be­fore Alex­ion, she brought her le­gal ex­pe­ri­ence to Boehringer In­gel­heim as the Ger­man phar­ma’s se­nior coun­sel in the US on­col­o­gy busi­ness unit.

→ Copen­hagen-based IO Biotech has en­list­ed Kei­th Ven­dola as CFO. Ven­dola brings to the ta­ble ex­pe­ri­ence from his times at Re­zo­lute, Co­herus, Eiger Bio­Phar­ma­ceu­ti­cals and Thresh­old Phar­ma­ceu­ti­cals (now Mol­e­c­u­lar Tem­plates).

Jisoo Park

Melin­ta Ther­a­peu­tics makes Peer Re­view for the sec­ond week in a row as the an­tibi­otics mak­er brings in Jisoo Park as head of busi­ness de­vel­op­ment, M&A and strat­e­gy. A vet­er­an of JP Mor­gan’s glob­al health­care team, Park was pre­vi­ous­ly VP of busi­ness de­vel­op­ment and M&A at Co­vis Phar­ma. This marks the sec­ond hire in as many weeks for Melin­ta as the com­pa­ny re­moved the in­ter­im tag from CFO Su­san Blum.

El­e­var Ther­a­peu­tics is adding some fresh faces to its lead­er­ship team with the ap­point­ments of Mau­reen Con­lan as CMO, Julie Boisvert as VP, reg­u­la­to­ry af­fairs and Do­minick Di­Pao­lo as VP, qual­i­ty as­sur­ance. Con­lan comes to the Salt Lake City-based com­pa­ny from Ra­dius Health; Boisvert hops aboard from BeiGene USA, where she served as se­nior di­rec­tor in reg­u­la­to­ry af­fairs; while Di­Pao­lo joins from qual­i­ty and com­pli­ance con­sul­tan­cy firm Qual­i­ty by De­sign.

Preethi Sun­daram

→ Hav­ing bat­tled it out in court over the ap­proval of ri­val Ja­cobus’ LEMS drug — a bat­tle that was ul­ti­mate­ly lostCat­a­lyst Phar­ma­ceu­ti­cals has tapped Preethi Sun­daram as chief prod­uct de­vel­op­ment of­fi­cer. Sun­daram comes to Cat­a­lyst af­ter an as­sort­ment of R&D and med­ical af­fairs roles in 16 years at Sanofi, rang­ing from glob­al project head in mul­ti­ple ther­a­peu­tic ar­eas to her lat­est re­spon­si­bil­i­ties as glob­al head of med­ical op­er­a­tions, gen­er­al med­i­cines busi­ness unit.

→ Austin, TX-based Ae­glea Bio­Ther­a­peu­tics has named Jonathan Alspaugh as CFO. Alspaugh makes the jump from Ever­core, where he most re­cent­ly served as a man­ag­ing di­rec­tor in the firm’s cor­po­rate ad­vi­so­ry busi­ness. Pri­or to that, Alspaugh was with Bar­clays Cap­i­tal.

Robert Mill­ham

CATO SMS, a glob­al provider of clin­i­cal re­search so­lu­tions, has bagged Robert Mill­ham as pres­i­dent of clin­i­cal tri­al op­er­a­tions. Mill­ham had a 17-year stint at Pfiz­er, where he led and con­tributed to the de­vel­op­ment of com­pounds against mul­ti­ple in­di­ca­tions of can­cer, in­clud­ing lung, breast, col­orec­tal and ovar­i­an. He was al­so the COO of Odonate Ther­a­peu­tics, SVP at Sy­neos Health and VP of strate­gic al­liances for Caris Life Sci­ences.

→ Peer Re­view reg­u­lar jCyte’s lead­er­ship keeps on grow­ing with chief de­vel­op­ment of­fi­cer and long­time Glax­o­SmithK­line ex­ec Adri­an Mor­ris. From 1997-2012, Mor­ris served in a num­ber of ca­pac­i­ties at the phar­ma gi­ant rang­ing from VP, glob­al com­mer­cial strat­e­gy in the res­pi­ra­to­ry pipeline to VP, di­ag­nos­tics busi­ness unit and Pan­dem­ic Cen­tre of Ex­cel­lence. Since he left GSK, Mor­ris had been man­ag­ing di­rec­tor at Phar­ma­co Con­sult­ing. For those scor­ing at home, jCyte has added a CFO, chief com­mer­cial of­fi­cer, gen­er­al coun­sel and oth­er ex­ecs in clin­i­cal de­vel­op­ment and med­ical af­fairs along with Mor­ris since Shan­non Blalock was pro­mot­ed to CEO in Feb­ru­ary.

Mark Alt­mey­er

Mark Alt­mey­er has been named chair­man of Dutch-based AM-Phar­ma’s su­per­vi­so­ry board. The Bris­tol My­ers, Ot­su­ka and Ax­o­vant vet was pres­i­dent and CEO of Arvelle be­fore An­geli­ni pur­chased it to ring in 2021 with a near­ly $1 bil­lion price tag.

Morn­ing­side Group co-founder Ger­ald Chan has added an­oth­er chair­man­ship, this time at Cog­ni­to Ther­a­peu­tics, which showed pos­i­tive Phase II da­ta with its lead dig­i­tal prod­uct for Alzheimer’s. Chan is al­so chair­man at Apel­lis and Stealth Bio­ther­a­peu­tics.

Lin­da Bain

→ Co­di­ak CFO Lin­da Bain is hop­ping on­to the board of di­rec­tors at VBI Vac­cines. Pri­or to her role at Co­di­ak, Bain was CFO at Ad­verum Biotech­nolo­gies; VP, fi­nance, busi­ness op­er­a­tions, and trea­sur­er at blue­bird bio; and held roles at Gen­zyme. In ad­di­tion to her new seat, Bain sits on the boards of Au­to­lus Ther­a­peu­tics and Arv­inas.

On­coRe­sponse has re­cruit­ed Cy­tomX pres­i­dent, CEO and chair­man Sean Mc­Carthy as an in­de­pen­dent di­rec­tor of its board. Mc­Carthy joined Cy­tomX in 2010 as CBO and has served as CEO since 2011. Pri­or to that role, Mc­Carthy was with Pap­pas Ven­tures, SGX Phar­ma­ceu­ti­cals and Mil­len­ni­um Phar­ma­ceu­ti­cals.

Jan Hill­son

→ Au­toim­mune and neu­rode­gen­er­a­tive dis­ease biotech Ele­don Phar­ma­ceu­ti­cals has elect­ed Jan Hill­son to the board of di­rec­tors. Hill­son, the SVP of clin­i­cal de­vel­op­ment at Alpine Im­mune Sci­ences, was once SVP of drug de­vel­op­ment for Chemo­Cen­tryx.

Chaired by Brent Saun­ders and with new CMO David Tanz­er join­ing the fray, the folks at eye dis­ease biotech OcuTer­ra have en­list­ed Richard Lind­strom and Sheri Rowen for their sci­en­tif­ic ad­vi­so­ry board. The founder of Min­neso­ta Eye Con­sul­tants, Lind­strom is an ad­junct pro­fes­sor emer­i­tus at the Uni­ver­si­ty of Min­neso­ta’s oph­thal­mol­o­gy de­part­ment. Rowen, a LASIK sur­geon in New­port Beach, CA, found­ed Mer­cy Med­ical Cen­ter’s oph­thal­mol­o­gy de­part­ment in Bal­ti­more 25 years ago.

Chimeric Ther­a­peu­tics has plucked up George Matcham as a non-ex­ec­u­tive di­rec­tor of its board. Matcham is a Cel­gene vet and was part of the com­pa­ny from its ear­ly days in 1988 to his re­tire­ment in 2018 — serv­ing as COO of Cel­gene Cel­lu­lar Ther­a­peu­tics and SVP of CAR-T CMC de­vel­op­ment. Matcham pre­vi­ous­ly sat on the board of In­stil Bio as an ad­vi­sor.



Source link